Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  47.00 0.6% 7,927.00 7,924.00 7,927.00 7,936.00 7,805.00 7,805.00 99,685 08:35:48
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 100.0 103,995

AstraZeneca, Merck Say Lynparza Demonstrates Long-Term Progression-Free Survival Benefit

18/09/2020 3:35pm

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Aug 2020 to Oct 2020

Click Here for more Astrazeneca Charts.

By Michael Dabaie


AstraZeneca and Merck & Co. said Lynparza demonstrated a long-term progression-free survival benefit versus placebo.

The companies said Lynparza demonstrated a long-term progression-free survival benefit versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy.

Five-year follow-up data from the Phase III SOLO-1 trial showed Lynparza reduced the risk of disease progression or death by 67% and improved progression-free survival to a median of 56.0 months versus 13.8 months for placebo.

At five years, 48.3% of patients treated with Lynparza remained free from disease progression versus 20.5% on placebo.

The median duration of treatment with Lynparza was 24.6 months, versus 13.9 months with placebo, the companies said.


Write to Michael Dabaie at


(END) Dow Jones Newswires

September 18, 2020 10:20 ET (14:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 08:50:48